$CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human studyResearch in context$

CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human studyResearch in context

Summary: Background: Current approved chimeric antigen receptor (CAR) T-cell products are autologous cell therapies that are costly and poorly accessible to patients. We aimed to evaluate the safety and antitumor activity of a novel off-the-shelf anti-CD19 CAR-engineered allogeneic double-negative...

Full description

Bibliographic Details
Main Authors:	Xibin Xiao, Hui Liu, Xi Qiu, Panpan Chen, Xian Li, Dan Wang, Guangrong Song, Yu Cheng, Liming Yang, Wenbin Qian
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	EClinicalMedicine
Subjects:	Double-negative T cells CD19-CAR-DNT cells B-cell lymphoma Safety Antitumor activity
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537024000956

Similar Items

Double-Negative T (DNT) Cells in Patients with Systemic Lupus Erythematosus
by: Dimitri Poddighe, et al.
Published: (2024-01-01)

Use of locally produced anti-CD19 CAR-T cells in the treatment of relapsed/refractory B-cell lymphomas in adults
by: N. E. Konoplya, et al.
Published: (2023-09-01)

Adaptive bridging radiation therapy for relapsed/refractory B-cell lymphoma patient undergoing CAR T-cell therapy: Case report
by: Hazim S. Ababneh, et al.
Published: (2024-09-01)

Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma
by: Yi Li Jiang, et al.
Published: (2024-02-01)

Successful CAR-T cell therapy in a refractory MCL patient with bacterial, fungal and COVID-19 infection: a case report
by: Vera Radici, et al.
Published: (2023-09-01)

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
by: Lefu Huang, et al.
Published: (2022-12-01)

Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL
by: Wanying Liu, et al.
Published: (2024-02-01)

Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
by: Ya Hwee Tan, et al.
Published: (2025-02-01)

CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma
by: Xiaoxi Zhou, et al.
Published: (2024-10-01)

The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management
by: Dito Anurogo, et al.
Published: (2024-07-01)

Incidentally cured psoriasis in a patient with refractory/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report
by: Song-yun Wang, et al.
Published: (2024-10-01)

Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?
by: Omran Saifi, MD, et al.
Published: (2020-06-01)

Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma
by: Naseem Esteghamat, et al.
Published: (2024-10-01)

Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: a systematic review and meta-analysis
by: Haixiang Wan, et al.
Published: (2024-09-01)

Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review
by: Sancho JM, et al.
Published: (2024-05-01)

CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES
by: Ugo Testa, et al.
Published: (2024-02-01)

Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma
by: Alexander D. Heini, et al.
Published: (2022-09-01)

Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma
by: Shuto Negishi, et al.
Published: (2024-01-01)

CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey
by: Goker Hakan, et al.
Published: (2024-08-01)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
by: Elad Jacoby
Published: (2019-06-01)

Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada
by: Jenna Shaw, et al.
Published: (2024-12-01)

Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration
by: Alice Sýkorová, et al.
Published: (2024-09-01)

Nanoarchitectonics in immobilization of DNT/TNT specific binding peptides on laser-induced graphene
by: Seda Kol, et al.
Published: (2024-01-01)

High-affinity promotor binding of YhaJ mediates a low signal leakage for effective DNT detection
by: Myeongbin Kim, et al.
Published: (2025-01-01)

CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA
by: Ugo Testa, et al.
Published: (2023-10-01)

Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical study
by: Danyang Li, et al.
Published: (2025-02-01)

A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma
by: Kanwal Asghar, et al.
Published: (2024-07-01)

Upregulation of CD19 by low‐dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma
by: Ying Ni, et al.
Published: (2025-01-01)

Broadening the horizon: potential applications of CAR-T cells beyond current indications
by: Hendrik Karsten, et al.
Published: (2023-11-01)

Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
by: Wenjie Zhang, et al.
Published: (2024-04-01)

FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells
by: Eugenio Galli, et al.
Published: (2024-02-01)

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01)

Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin’s lymphoma
by: David G. Frame, et al.
Published: (2024-06-01)

Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas
by: Daniel Atar, et al.
Published: (2022-09-01)

Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) FL with CAR-T Cell Therapy: A Vodcast and Case Example
by: Kai Hübel
Published: (2024-03-01)

Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?
by: Peng-Fei Zhang, et al.
Published: (2024-03-01)

Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel)
by: Yuan Tian, et al.
Published: (2025-02-01)

Cell membrane patches transfer CAR molecules from a cellular depot to conventional T cells for constructing innovative fused-CAR-T cells without necessitating genetic modification
by: Jing Hu, et al.
Published: (2024-08-01)

CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
by: Luca Castagna, et al.
Published: (2015-02-01)

Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and allogeneic feeder cells in patients diagnosed with B-cell non-Hodgkin lymphoma and acute myeloid leukemia
by: Martin Mucha, et al.
Published: (2024-08-01)